Linnaeus Therapeutics

Clinical-stage biopharmaceutical company developing small-molecule therapeutics that activate the G protein-coupled estrogen receptor (GPER). Founded in 2016 as a University of Pennsylvania spinout through the Penn Center for Innovation UPstart incubator, it is advancing lead candidate LNS8801, an oral selective GPER agonist dosed in more than 100 patients in a phase 1/2 advanced-cancer study, toward oncology, cardiometabolic and healthspan-related indications, backed by an ARPA-H PROSPR contract of up to $22 million and selection into the NIA Interventions Testing Program. Financial backers include Kairos Ventures, the Penn Medicine Co-Investment Fund and GenHenn Capital, and the company is headquartered in Haddonfield, New Jersey.

  • Seed
  • Biotechnology
  • Clinical Trials
  • Healthtech
  • Pharmaceuticals
  • Healthcare & Life Sciences

1

Round

1

Industry

5

Tags

Nov 16, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 16, 2026

    $3.7M

    Seed

    Article coming soon.

Pricing

Research Linnaeus Therapeutics — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Linnaeus Therapeutics is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational